David Risinger, an analyst from Leerink Partners, has initiated a new Buy rating on First Tracks Biotherapeutics Inc (TRAX).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
David Risinger has given his Buy rating due to a combination of factors, including the view that TRAX represents an attractive “event-driven” opportunity with several near-term data and partnership catalysts. He highlights that the company’s two lead immunology programs, targeting CD122 and BDCA2, address high unmet medical needs and are supported by partial validation from competing agents in similar pathways.
Risinger also underscores that each asset in TRAX’s pipeline shows potential for clinical and commercial differentiation, which could justify substantial upside if trial results are favorable. In addition, he considers the current market capitalization reasonable relative to peers and the risk-adjusted prospects, and his DCF analysis supports a price target meaningfully above the current share price, reinforcing his Outperform/Buy stance.
In another report released yesterday, J.P. Morgan also initiated coverage with a Buy rating on the stock with a $31.00 price target.